MEIP - CONSENSUS CO - MEI Pharma, Inc.

The daily price action for MEI Pharma, Inc. (MEIP) shown on this chart reflects a current value of . The business relies on its scientific authority gained through the development of cutting-edge methods for combating hematologic malignancies. However, the organization is currently undergoing a wind-down and shareholder payout phase following failed trials, as confirmed by the SEC. Global conflicts further complicate the situation, hindering raw material logistics and patent protection.

The colossal scaling potential of MEI Pharma, Inc. (MEIP) in hematologic oncology directly drives changes in the consensus valuation of the stock, reflecting market expectations for the global rollout of its drugs. This indicator represents an aggregated discounted cash flow model, where analysts continuously recalculate the cost of capital to determine the fair market value of the company's assets.